Navigation Links
Discovery of genetic mutation in Leigh syndrome
Date:8/11/2009

This release is available in French.

Researchers at the Montreal Neurological Institute and Hospital (The Neuro), McGill University have discovered a genetic mutation underlying late-onset Leigh syndrome, a rare inherited metabolic disorder characterized by the degeneration of the central nervous system. The study published in Nature Genetics, provides vital insights into the cell biology of this neurological disorder and will lead to the development of diagnostic and predictive tests allowing for family and genetic counseling.

Leigh syndrome usually begins in early childhood and is caused by genetic mutations which result in mitochondrial dysfunction. Mitochondria are compartments in the cell which have their own DNA and function to supply energy to the body. Damage and dysfunction to mitochondrial DNA is a factor in more than 40 types of metabolic diseases and disorders, including Leigh syndrome. The first signs of the disorder are often poor sucking ability, loss of head control, and loss of acquired motor skills or movement. As the disorder progresses, symptoms may also include generalized weakness, lack of muscle tone, episodes of lactic acidosis (the body becomes more acidic than normal) and breathing problems. Death usually occurs within a few years. In rare cases, "late onset" Leigh syndrome begins during adolescence or early adulthood and progresses more slowly than the classical form. Currently, there is no cure and treatment is limited and not very effective.

"Defects in the protein production machinery, or translation, are among the most common causes of mitochondrial disease," says Dr. Eric Shoubridge, neuroscientist at The Neuro and lead investigator in the study, "and the mechanisms that regulate translation have until now remained largely unknown."

"Using molecular biological techniques and DNA analysis, we were able to pin point a mutation in the TACO1 gene which encodes a translational activator important for the proper production of a protein called COX1. This study is also the first to identify a protein of this nature in humans.COX1 is a critical component of one of the enzymes in the energy production pathway in cells, and disruptions in COX1 production, lead to loss of enzyme activity and the symptoms in Leigh Syndrome."

Researchers in Dr. Shoubridge's lab at The Neuro were the first to discover the gene implicated in the most common form of Leigh syndrome and are now studying various forms of the disease. This includes the French-Canadian form common in the Saguenay-Lac St-Jean region of Quebec which is associated with a different genetic mutation, but the same biochemical defect, and similar presentation to the form investigated in this study. Neuro researchers are also collaborating on Le Grand Defi led by Pierre Lavoie, an initiative to raise awareness and funds for research into the disease.


'/>"/>

Contact: Anita Kar
anita.kar@mcgill.ca
514-398-3376
McGill University
Source:Eurekalert

Related biology news :

1. Discovery to aid in future treatments of third-world parasites
2. New discovery suggests trees evolved camouflage defense against long extinct predator
3. Down Under dinosaur burrow discovery provides climate change clues
4. GUMC discovery highlights new direction for drug discovery
5. Discovery may provide new treatments for alcohol dependence
6. New nanoparticles could revolutionize therapeutic drug discovery
7. Discovery of a water snake that startles fish in a way that makes them flee into its jaws
8. New discovery suggests mammoths survived in Britain until 14,000 years ago
9. Discovery of the cells water gate may lead to new cancer drugs
10. Aussie and Kiwi researchers make double MS genetic discovery
11. Discovery raises new doubts about dinosaur-bird links
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: